FDA Issues Early Communication About An Ongoing Safety Review Of Aprotinin Injection

Last week, FDA was notified that a Canadian research group stopped a study on Trasylol because the drug appeared to increase the risk for death compared to the other antifibrinolytic drugs used in the study. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. The data also suggested that fewer patients receiving the drug experienced serious bleeding events. [click link for full article]

More: continued here

Filed under: Cardiovascular on October 30th, 2007